Next Pharmaceuticals Acquires Rights to Sytrinol Heart-Health Ingredient
Research shows Sytrinol significantly improves total cholesterol, LDL cholesterol, and triglyceride levels up to 30%, 27%, and 34%, respectively.
Next Pharmaceuticals (Salinas, CA) has purchased the future worldwide distribution rights to Sytrinol, a patented ingredient aimed at heart health, derived from natural citrus and palm fruit extracts. Supplier Proprietary Nutritionals Inc. (Kearny, NJ) holds the distribution rights to Sytrinol until the end of this year. Next Pharmaceuticals will own the rights, including patents, trademarks, and scientific property, purchased from the ingredient’s Canada-based research and development firm KGK Synergize.
Sytrinol combines polymethoxylated flavones and delta-, gamma-, and alpha-tocotrienols.The companies say clinical research shows Sytrinol significantly improves total cholesterol, LDL cholesterol, and triglyceride levels up to 30%, 27%, and 34%, respectively, compared to placebo, as well as increases HDL cholesterol.
